| Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer (NCT06016179) | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 2024-01-30 |
| Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma (NCT06105554) | M.D. Anderson Cancer Center | 2024-01-30 |
| A Study of Simmitinib Plus SG001 in Advanced Solid Tumors (NCT06132217) | Shanghai Runshi Pharmaceutical Technology Co., Ltd | 2024-01-30 |
| A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (NCT05916313) | Boehringer Ingelheim | 2024-01-30 |
| A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma (NCT06207305) | M.D. Anderson Cancer Center | 2024-01-30 |
| Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-NS250 and IY-NT-SR (NCT06725992) | Il-Yang Pharm. Co., Ltd. | 2024-01-30 |
| P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants (NCT06079775) | Qpex Biopharma, Inc. | 2024-01-30 |
| Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults (NCT06205056) | U.S. Army Medical Research and Development Command | 2024-01-30 |
| Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers (NCT06130254) | M.D. Anderson Cancer Center | 2024-01-30 |
| Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects (NCT06363292) | Laboratorios Sophia S.A de C.V. | 2024-01-30 |
| Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas) (NCT06024824) | Cancer Trials Ireland | 2024-01-30 |
| Phase 1 Healthy Volunteer Burn Therapy Study (NCT06223009) | Neomatrix Therapeutics, Inc. | 2024-01-30 |
| CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer (NCT05942300) | Lan Coffman | 2024-01-30 |
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer (NCT06328387) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2024-01-29 |
| A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) (NCT06241950) | Sarepta Therapeutics, Inc. | 2024-01-29 |
| Barre Exercise in Parkinson's (NCT06203990) | Washington University School of Medicine | 2024-01-29 |
| CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (NCT06209619) | Nathan Denlinger | 2024-01-29 |
| Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer (NCT05553522) | Baptist Health South Florida | 2024-01-29 |
| Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer (NCT05990543) | Korea University Anam Hospital | 2024-01-29 |
| A Research Study of a New Medicine (NNC0650-0013) in Healthy Men (NCT06284798) | Novo Nordisk A/S | 2024-01-29 |
| Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness (NCT05968144) | University of Maryland, Baltimore | 2024-01-29 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants (NCT06144697) | Bristol-Myers Squibb | 2024-01-29 |
| Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine (NCT06294262) | LiteVax BV | 2024-01-29 |
| A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants (NCT06148181) | AbbVie | 2024-01-29 |
| Feasibility of Semaglutide in Advanced Lung Disease (NCT05746039) | University of Pennsylvania | 2024-01-29 |
| A Study of Pembrolizumab and Cryoablation in People With Breast Cancer (NCT06246968) | Memorial Sloan Kettering Cancer Center | 2024-01-29 |
| Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma (NCT04466475) | Fred Hutchinson Cancer Center | 2024-01-27 |
| Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (NCT06072040) | Auregen Biotherapeutics, SA | 2024-01-26 |
| Single and Multiple Ascending Doses and Food Effect Study of TRD205 in Healthy Volunteers (NCT07123428) | Beijing Tide Pharmaceutical Co., Ltd | 2024-01-26 |
| An Evaluation of The Absolute Bioavailability of TH104 (NCT06198686) | Tharimmune Inc | 2024-01-26 |
| Decreasing Emergence Delirium With Personalized Music (NCT06236477) | Washington University School of Medicine | 2024-01-26 |
| Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 (NCT06078566) | Auregen Biotherapeutics, SA | 2024-01-26 |
| PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors (NCT06244992) | Pyrotech Therapeutics, Inc. | 2024-01-26 |
| A Clinical Study of T3011 in Subjects With Advanced Melanoma (NCT06214156) | Shanghai Pharmaceuticals Holding Co., Ltd | 2024-01-26 |
| Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1 (NCT06069791) | Yale University | 2024-01-26 |
| Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects (NCT06221813) | Public Health Vaccines LLC | 2024-01-26 |
| Study of Intra-articular Allocetra in Knee Osteoarthritis (NCT06233474) | Enlivex Therapeutics Ltd. | 2024-01-26 |
| A Phase I Study of XH-S004 in Healthy Volunteers (NCT06236841) | S-INFINITY Pharmaceuticals Co., Ltd | 2024-01-26 |
| A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA (NCT06049342) | Nuwacell Biotechnologies Co., Ltd. | 2024-01-25 |
| Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) (NCT06191796) | Exelixis | 2024-01-25 |
| A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety (NCT06070597) | Boehringer Ingelheim | 2024-01-25 |
| A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants (NCT06221475) | Bayer | 2024-01-25 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors (NCT06004245) | Vividion Therapeutics, Inc. | 2024-01-25 |
| A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies (NCT06224855) | Hangzhou DAC Biotechnology Co., Ltd. | 2024-01-24 |
| Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation (NCT06138587) | Dana-Farber Cancer Institute | 2024-01-24 |
| Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004) (NCT06179407) | Merck Sharp & Dohme LLC | 2024-01-24 |
| Clinical Trial of BT02 in Patients With Advanced Solid Tumors (NCT06404905) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-24 |
| Ergogenic Effects of Sportlegs (NCT06371521) | Christopher Bell | 2024-01-24 |
| Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age (NCT05660980) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-24 |
| Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants (NCT06278389) | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | 2024-01-24 |
| Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Subjects After Subcutaneous Injection of TISA-818-Inj (NCT07337044) | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | 2024-01-24 |
| Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer (NCT06110195) | University of Chicago | 2024-01-24 |
| Bupivacaine Hydrochloride for Pain Control in Cutaneous Surgery (NCT04260854) | Northwestern University | 2024-01-24 |
| UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 (NCT05535855) | University of Colorado, Denver | 2024-01-24 |
| A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate (NCT05727267) | Universitätsklinikum Hamburg-Eppendorf | 2024-01-23 |
| Phase 1/2a Study of ANPD001 in Parkinson Disease (NCT06344026) | Aspen Neuroscience | 2024-01-23 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers (NCT06258213) | Atom Therapeutics Co., Ltd | 2024-01-23 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC (NCT06186414) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2024-01-23 |
| Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older (NCT06237296) | Sanofi Pasteur, a Sanofi Company | 2024-01-23 |
| ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors (NCT06161493) | Haider Mahdi | 2024-01-23 |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer (NCT06179069) | Zai Lab (Shanghai) Co., Ltd. | 2024-01-23 |
| A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche) (NCT06886659) | Incepta Pharmaceuticals Ltd | 2024-01-23 |
| Organ Protective Effect of Cetirizine In Patients With Severe Burns (NCT06126991) | Ruijin Hospital | 2024-01-23 |
| A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055) (NCT06719570) | Merck Sharp & Dohme LLC | 2024-01-23 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants (NCT06116617) | Sirius Therapeutics Co., Ltd. | 2024-01-23 |
| Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease (NCT06356662) | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 2024-01-23 |
| A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants (NCT06214481) | Amgen | 2024-01-23 |
| Comparative Pharmacokinetic Study of Aprepitant Injection in Humans (NCT06226506) | The Affiliated Hospital of Qingdao University | 2024-01-23 |
| AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. (NCT06137144) | AstraZeneca | 2024-01-23 |
| A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT06153251) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2024-01-23 |
| How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants (NCT07573449) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2024-01-22 |
| A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) (NCT06699329) | Merck Sharp & Dohme LLC | 2024-01-22 |
| Molecular Imaging Study of Harmine/DMT: a Basic Research Approach (NCT06252506) | Insel Gruppe AG, University Hospital Bern | 2024-01-22 |
| A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer (NCT06199466) | M.D. Anderson Cancer Center | 2024-01-22 |
| A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 (NCT06240728) | NextPoint Therapeutics, Inc. | 2024-01-22 |
| DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers (NCT06132113) | Boehringer Ingelheim | 2024-01-22 |
| A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis (NCT06191042) | selectION Therapeutics GmbH | 2024-01-22 |
| Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6 (NCT06228482) | University of California, Davis | 2024-01-22 |
| Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults (NCT06125691) | Arcturus Therapeutics, Inc. | 2024-01-22 |
| A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients (NCT06063590) | Cellcolabs Clinical SPV Limited | 2024-01-22 |
| Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment (NCT05533242) | University Hospital Muenster | 2024-01-22 |
| Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis (NCT06120816) | Sanotize Research and Development corp. | 2024-01-20 |
| CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy (NCT06212154) | Institute of Hematology & Blood Diseases Hospital, China | 2024-01-20 |
| Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe (NCT06050291) | NewAmsterdam Pharma | 2024-01-20 |
| A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors (NCT06031584) | Sichuan Baili Pharmaceutical Co., Ltd. | 2024-01-19 |
| A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines (NCT06199336) | JHM BioPharma (Tonghua) Co. , Ltd. | 2024-01-19 |
| A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (NCT06120075) | Arcus Biosciences, Inc. | 2024-01-19 |
| A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients (NCT06249919) | Neuracle Science Co., LTD. | 2024-01-19 |
| Tuberculosis Vaccine in Healthy Indian Adults (NCT06438978) | Bharat Biotech International Limited | 2024-01-19 |
| Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors (NCT06171750) | Ankyra Therapeutics, Inc | 2024-01-19 |
| A Usability Study of iTEAR100 For Combined EyeLid Microblepharoexfoliation and Neurostimulation (NCT06235450) | Olympic Ophthalmics, Inc. | 2024-01-19 |
| HS-IT101 Injection in the Treatment of Advanced Solid Tumors (NCT06342336) | Qingdao Sino-Cell Biomedicine Co., Ltd. | 2024-01-18 |
| Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease (NCT06206824) | Perha Pharmaceuticals | 2024-01-18 |
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy (NCT05985954) | M.D. Anderson Cancer Center | 2024-01-18 |
| JX09 SAD/MAD in Healthy Participants (NCT06183671) | Ji Xing Pharmaceuticals Australia Pty Ltd | 2024-01-18 |
| The Efface of Lidocaine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy (NCT07248332) | Liaquat National Hospital & Medical College | 2024-01-18 |
| JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors (NCT06226766) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2024-01-18 |
| the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C (NCT06132360) | Shanghai Rona Therapeutics Co., Ltd. | 2024-01-18 |
| A Study of KK2269 in Adult Participants With Solid Tumors (NCT06266299) | Kyowa Kirin Co., Ltd. | 2024-01-18 |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) (NCT06056310) | EMD Serono Research & Development Institute, Inc. | 2024-01-18 |